2011-01-05
Affibody to Present at CHI's 10th Annual PepTalk in San Diego
Affibody AB will give a presentation titled “Engineering of the Albumin Binding Domain (ABD) for Half-life Extension Applications” at CHI's 10th Annual PepTalk 2011, taking place January 10-14, 2011 in San Diego, California.
Ass. Prof Fredrik Frejd will present results on the engineering of the Albumod™ platform. The presentation will be made at 7:30am – 8:15am on Thursday January 13 in the track: “Antibodies for the 21st Century”.
About the Albumod™ platform
Affibody’s Albumod™ technology is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life, potentially allowing for less frequent dosing and lower peak concentrations in blood with a decreased risk for adverse events. Furthermore, the Albumod™ technology may potentially be used to evade an immune response. In addition to these possible patient safety benefits, the overall treatment costs may be reduced.
About Affibody
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.
Affibody has ongoing commercial relationships with several companies including Amylin, Swedish Orphan Biovitrum, GE, and Thermo Fisher.
Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include HealthCap and Investor Growth Capital.
Further information can be found at: www.affibody.se.